Therapeutic Area | MeSH |
---|---|
infections | D007239 |
neoplasms | D009369 |
Tradename | Proper name | Company | Number | Date | Products |
---|---|---|---|---|---|
Bavencio | avelumab | EMD Serono | N-761049 RX | 2017-03-23 | 1 products |
Brand Name | Status | Last Update |
---|---|---|
bavencio | Biologic Licensing Application | 2024-01-30 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
merkel cell carcinoma | EFO_1001471 | D015266 | C4A |
transitional cell carcinoma | — | D002295 | — |
Expiration | Code | ||
---|---|---|---|
avelumab, Bavencio, EMD Serono, Inc. | |||
2024-03-23 | Orphan excl. |
Code | Description |
---|---|
J9023 | Injection, avelumab, 10 mg |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Neoplasms | D009369 | — | C80 | 27 | 17 | 2 | — | 3 | 41 |
Non-small-cell lung carcinoma | D002289 | — | — | 16 | 16 | 3 | — | — | 25 |
Renal cell carcinoma | D002292 | EFO_0000376 | — | 4 | 10 | 3 | — | 8 | 24 |
Urologic neoplasms | D014571 | — | C64-C68 | 7 | 12 | 1 | — | 4 | 22 |
Merkel cell carcinoma | D015266 | EFO_1001471 | C4A | 7 | 13 | 1 | — | 1 | 17 |
Urinary bladder neoplasms | D001749 | — | C67 | 3 | 10 | 1 | — | 2 | 13 |
Squamous cell carcinoma of head and neck | D000077195 | — | — | 6 | 3 | 2 | — | — | 9 |
Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 4 | 1 | 4 | — | — | 8 |
Triple negative breast neoplasms | D064726 | — | — | 4 | 4 | 1 | — | — | 7 |
Adenocarcinoma | D000230 | — | — | — | 5 | 1 | — | — | 6 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Colorectal neoplasms | D015179 | — | — | 6 | 15 | — | — | — | 17 |
Breast neoplasms | D001943 | EFO_0003869 | C50 | 6 | 10 | — | — | — | 14 |
Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 9 | 9 | — | — | — | 11 |
Melanoma | D008545 | — | — | 4 | 4 | — | — | 1 | 7 |
Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 3 | 5 | — | — | — | 6 |
Squamous cell carcinoma | D002294 | — | — | 2 | 5 | — | — | — | 6 |
Castration-resistant prostatic neoplasms | D064129 | — | — | 4 | 3 | — | — | — | 5 |
Sarcoma | D012509 | — | — | 5 | 2 | — | — | — | 5 |
Squamous cell neoplasms | D018307 | — | — | 2 | 4 | — | — | — | 5 |
Glioblastoma | D005909 | EFO_0000515 | — | 2 | 4 | — | — | — | 5 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Mycosis fungoides | D009182 | — | C84.0 | 2 | — | — | — | — | 2 |
Sezary syndrome | D012751 | — | C84.1 | 1 | — | — | — | — | 1 |
Large-cell lymphoma anaplastic | D017728 | — | C84.6 | 1 | — | — | — | — | 1 |
T-cell lymphoma peripheral | D016411 | — | — | 1 | — | — | — | — | 1 |
Glioma | D005910 | EFO_0000520 | — | 1 | — | — | — | — | 1 |
Follicular lymphoma | D008224 | — | C82 | 1 | — | — | — | — | 1 |
Pancreatic ductal carcinoma | D021441 | — | — | 1 | — | — | — | — | 1 |
Lymphoma | D008223 | — | C85.9 | 1 | — | — | — | — | 1 |
Mantle-cell lymphoma | D020522 | — | C83.1 | 1 | — | — | — | — | 1 |
Meningioma | D008579 | EFO_0003098 | D32.9 | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Heart diseases | D006331 | EFO_0003777 | I51.9 | — | — | — | — | 2 | 2 |
Myocarditis | D009205 | — | I51.4 | — | — | — | — | 2 | 2 |
Autoimmune diseases | D001327 | HP_0002960 | M30-M36 | — | — | — | — | 2 | 2 |
Cardiovascular diseases | D002318 | HP_0001626 | — | — | — | — | — | 1 | 1 |
Cardiomyopathies | D009202 | EFO_0000318 | I42 | — | — | — | — | 1 | 1 |
Pericarditis | D010493 | EFO_0007427 | I30 | — | — | — | — | 1 | 1 |
Vasculitis | D014657 | HP_0002633 | — | — | — | — | — | 1 | 1 |
Myositis | D009220 | EFO_0000783 | G72.49 | — | — | — | — | 1 | 1 |
Arthritis | D001168 | HP_0001369 | M05-M14 | — | — | — | — | 1 | 1 |
Endocrine system diseases | D004700 | EFO_0001379 | E34.9 | — | — | — | — | 1 | 1 |
Drug common name | Avelumab |
INN | avelumab |
Description | Avelumab, sold under the brand name Bavencio, is a fully human monoclonal antibody medication for the treatment of Merkel cell carcinoma, urothelial carcinoma, and renal cell carcinoma.
|
Classification | Antibody |
Drug class | monoclonal antibodies |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | 5GRJ |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL3833373 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | DB11945 |
UNII ID | KXG2PJ551I (ChemIDplus, GSRS) |